ClinicalTrials.gg
CompletedNCT07231861Updated Sep 18, 2026

Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers

A Phase 1 interventional study of AJU-R713 and R713R in Bronchial Asthma and Perennial Allergic Rhinitis, sponsored by AJU Pharm Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by AJU Pharm Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 141 studies in Asthma with a site in Korea, Republic of — 13 open to participants now, 23 under way, 9 of them phase 3. Asthma · Korea, Republic of.

Enrollment
109th of 117
62 · median 389
Started
2025
with 6 others
Phase 1
4 of 141
none open now
Registered
136th of 141
by date

Among the 141 studies in Asthma with a site in Korea, Republic of, this one is the 109th largest by enrollment of the 117 interventional ones that give a count, is one of 7 that started in 2025, is one of 4 in phase 1, and was the 136th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

13 of the 141 studies in Asthma with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Asthma with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.

Read the detailed description

This study evaluates the pharmacokinetic characteristics and safety of pranlukast in healthy adults. It is a randomized, open-label, single-dose, two-period crossover trial conducted under fasting conditions. Pharmacokinetic samples are collected up to 24 hours after dosing, and standard safety assessments are performed throughout the study.

03

Conditions studied

  • Bronchial Asthma
  • Perennial Allergic Rhinitis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19 years or older at the time of screening.
  • (BMI) between 18 and 30 kg/m².

    • Male subjects: body weight ≥ 50 kg.
    • Female subjects: body weight ≥ 45 kg.
  • Clinically healthy based on medical history, physical examination, vital signs, (ECG), and laboratory test results, as determined by the investigator.
  • Willing and able to provide written after receiving a full explanation of the study.
  • Subjects (and their partners, if applicable) agree to use highly effective, non-hormonal from the first dosing day until one week after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.
  • Participation in any clinical trial involving products within 6 months prior to the first dose.
  • Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.
  • History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).
  • Known to the investigational product or its components.
  • Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria.
  • History of psychiatric illness.
  • Pregnant or breastfeeding women, or women with a possibility of pregnancy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Pranlukast Test Formulation

    Two-period, single-dose, crossover study

    Drug: AJU-R713 · Drug: R713R

  • Experimental
    Pranlukast Reference Formulation

    Two-period, single-dose, crossover study (reversed order)

    Drug: AJU-R713 · Drug: R713R

Interventions

  • DrugAJU-R713

    Oral formulation

  • DrugR713R

    Oral formulation

06

What researchers measure

Primary outcomes

  1. Cmax of Pranlukast

    To assess the maximum observed plasma concentration (Cmax) of Pranlukast

    Time frame: 0 hour ~ 24 hour after drug administration

  2. AUCt of Pranlukast

    To assess the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Pranlukast

    Time frame: 0 hour ~ 24 hour after drug administration

07

Study locations

1 site
  • H Plus Yangji Hospital
    Seoul, 08779, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Dec 2025, 0 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 0 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 17, 2025
StartActual
Dec 12, 2025
Primary completionActual
Dec 21, 2025
CompletionActual
Jan 7, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07231861
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Dec 12, 2025
Primary completion
Dec 21, 2025
Completion
Jan 7, 2026
Last update
Sep 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion